专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20100285595A1 MYOGLOBIN AS EARLY PREDICTOR OF MYOCARDIAL INFARCTION 失效
标题翻译： MYOGLOBIN作为心肌梗塞早期预后因素
公开(公告)号：US20100285595A1
公开(公告)日：2010-11-11
申请号：US12720063
申请日：2010-03-09
申请人： Georg Hess , Hendrik Huedig , Rosemarie Kientsch-Engel , Dietmar Zdunek
发明人： Georg Hess , Hendrik Huedig , Rosemarie Kientsch-Engel , Dietmar Zdunek
IPC分类号： G01N33/72
CPC分类号： G01N33/6887 , G01N2333/805 , G01N2800/324
摘要： The present invention relates to a method for diagnosing myocardial infarction in a subject who suffers from acute coronary syndrome and has a cardiac troponin level, which is detectable, but lower than the level that is considered as being indicative for a myocardial infarction. Moreover, the present invention relates to a method for identifying a subject being susceptible to cardiac intervention, wherein the subject suffers from acute coronary syndrome and has a cardiac troponin level which is detectable, but lower than a level that is considered as being indicative for a myocardial infarction. The methods of the present invention are based on the determination of myoglobin and, optionally, Heart-type fatty acid binding protein (H-FABP) in a sample of said subject and comparing the amount of myoglobin and, optionally, H-FABP to reference amounts. Also comprised by the present invention are kits or devices to carry out the methods of the present invention.
摘要翻译：本发明涉及一种用于诊断患有急性冠状动脉综合征且具有心肌肌钙蛋白水平的受试者心肌梗塞的方法，其可检测但低于被认为是指示心肌梗塞的水平。此外，本发明涉及用于识别易受心脏干预的受试者的方法，其中所述受试者患有急性冠状动脉综合征，并且具有可检测但是低于被认为是指示性的水平的心脏肌钙蛋白水平心肌梗死本发明的方法是基于在所述受试者的样品中测定肌红蛋白和任选的心脏型脂肪酸结合蛋白（H-FABP），并将肌红蛋白和任选的H-FABP的量与参考金额本发明还包括用于实施本发明方法的试剂盒或装置。

2. 发明申请

US20100159491A1 H-FABP AS EARLY PREDICTOR OF MYOCARDIAL INFARCTION 失效
标题翻译： H-FABP作为心肌梗塞的早期预后因素
公开(公告)号：US20100159491A1
公开(公告)日：2010-06-24
申请号：US12623495
申请日：2009-11-23
申请人： Georg Hess , Hendrik Huedig , Rosemarie Kientsch-Engel , Dietmar Zdunek
发明人： Georg Hess , Hendrik Huedig , Rosemarie Kientsch-Engel , Dietmar Zdunek
IPC分类号： G01N33/68 , G01N33/53
CPC分类号： G01N33/6893 , G01N2800/324
摘要： The present invention relates to a method for diagnosing myocardial infarction in a subject who suffers from acute coronary syndrome and has a cardiac troponin level which is detectable but lower than the level that is considered as being indicative for a myocardial infarction. Moreover, the present invention relates to a method for identifying a subject being susceptible to cardiac intervention, wherein the subject suffers from acute coronary syndrome and has a cardiac troponin level which is detectable but lower than a level that is considered as being indicative for a myocardial infarction. The methods of the present invention are based on the determination of H-FABP and, optionally, myoglobin in a sample of the subject and comparing the amount of H-FABP and, optionally, myoglobin to reference amounts.
摘要翻译：本发明涉及一种用于诊断患有急性冠状动脉综合征并且具有可检测但低于被认为是指示心肌梗死的水平的心肌肌钙蛋白水平的受试者心肌梗塞的方法。此外，本发明涉及用于识别易受心脏干预的受试者的方法，其中所述受试者患有急性冠状动脉综合征，并且具有可检测但低于被认为是指示心肌的水平的心肌肌钙蛋白水平梗死。本发明的方法是基于H-FABP和任选地在受试者样品中的肌红蛋白的测定，并将H-FABP和任选的肌红蛋白的量与参考量进行比较。

3. 发明授权

US08062857B1 H-FABP as early predictor of myocardial infarction 失效
标题翻译： H-FABP作为心肌梗死的早期预测因子
公开(公告)号：US08062857B1
公开(公告)日：2011-11-22
申请号：US12623495
申请日：2009-11-23
申请人： Georg Hess , Hendrik Huedig , Rosemarie Kientsch-Engel , Dietmar Zdunek
发明人： Georg Hess , Hendrik Huedig , Rosemarie Kientsch-Engel , Dietmar Zdunek
IPC分类号： G01N33/53 , G01N31/00
CPC分类号： G01N33/6893 , G01N2800/324
摘要： The present invention relates to a method for diagnosing myocardial infarction in a subject who suffers from acute coronary syndrome and has a cardiac troponin level which is detectable but lower than the level that is considered as being indicative for a myocardial infarction. Moreover, the present invention relates to a method for identifying a subject being susceptible to cardiac intervention, wherein the subject suffers from acute coronary syndrome and has a cardiac troponin level which is detectable but lower than a level that is considered as being indicative for a myocardial infarction. The methods of the present invention are based on the determination of H-FABP and, optionally, myoglobin in a sample of the subject and comparing the amount of H-FABP and, optionally, myoglobin to reference amounts.
摘要翻译：本发明涉及一种用于诊断患有急性冠状动脉综合征并且具有可检测但低于被认为是指示心肌梗死的水平的心肌肌钙蛋白水平的受试者心肌梗塞的方法。此外，本发明涉及用于识别易受心脏干预的受试者的方法，其中所述受试者患有急性冠状动脉综合征，并且具有可检测但低于被认为是指示心肌的水平的心肌肌钙蛋白水平梗死。本发明的方法是基于H-FABP和任选地在受试者样品中的肌红蛋白的测定，并将H-FABP和任选的肌红蛋白的量与参考量进行比较。

4. 发明授权

US07977105B2 Myoglobin as early predictor of myocardial infarction 失效
标题翻译：肌红蛋白作为心肌梗死的早期预测因子
公开(公告)号：US07977105B2
公开(公告)日：2011-07-12
申请号：US12720063
申请日：2010-03-09
申请人： Georg Hess , Hendrik Huedig , Rosemarie Kientsch-Engel , Dietmar Zdunek
发明人： Georg Hess , Hendrik Huedig , Rosemarie Kientsch-Engel , Dietmar Zdunek
IPC分类号： G01N33/72 , G01N33/48
CPC分类号： G01N33/6887 , G01N2333/805 , G01N2800/324
摘要： Disclosed is a method for diagnosing myocardial infarction in a subject who suffers from acute coronary syndrome and has a cardiac troponin level, which is detectable, but lower than the level that is considered as being indicative for a myocardial infarction. Also disclosed is a method for identifying a subject being susceptible to cardiac intervention, wherein the subject suffers from acute coronary syndrome and has a cardiac troponin level which is detectable, but lower than a level that is considered as being indicative for a myocardial infarction. These methods are based on the determination of myoglobin and, optionally, Heart-type fatty acid binding protein (H-FABP) in a sample of the subject and comparing the amount of myoglobin and, optionally, H-FABP to reference amounts. Also disclosed are kits or devices to carry out the methods.
摘要翻译：公开了一种用于诊断患有急性冠状动脉综合征且具有心肌肌钙蛋白水平的受试者心肌梗塞的方法，其可检测但低于被认为是指示心肌梗塞的水平。还公开了用于鉴定易受心脏干预的受试者的方法，其中受试者患有急性冠状动脉综合征，并且具有可检测但低于被认为是指示心肌梗死的水平的心肌肌钙蛋白水平。这些方法基于测定受试者样品中的肌红蛋白和任选的心脏型脂肪酸结合蛋白（H-FABP），并将肌红蛋白和任选的H-FABP的量与参考量进行比较。还公开了用于执行方法的套件或装置。

5. 发明申请

US20100159608A1 ASSESSING HEART FAILURE IN PATIENTS WITH ATRIAL FIBRILLATIN USING GDF-15 AND NATRIURETIC PEPTIDES 有权
标题翻译：使用GDF-15和NATRIURETIC PEPTIES评估患有ATRIAL FIBRILLATIN患者的心脏失效
公开(公告)号：US20100159608A1
公开(公告)日：2010-06-24
申请号：US12621560
申请日：2009-11-19
申请人： Georg Hess , Andrea Horsch , Hendrik Huedig , Dietmar Zdunek
发明人： Georg Hess , Andrea Horsch , Hendrik Huedig , Dietmar Zdunek
IPC分类号： G01N33/68 , B01J19/00
CPC分类号： G01N33/6863 , G01N33/74 , G01N2333/495 , G01N2333/58 , G01N2800/324 , G01N2800/325
摘要： The present invention is concerned with methods and devices for medical diagnosis. Specifically, it relates to a method of diagnosing heart failure in a subject exhibiting atrial fibrillation, the method comprising determining the amount of GDF-15 in a sample of the subject and comparing the amount of GDF-15 with a suitable reference amount whereby heart failure is to be diagnosed. Moreover, the present invention relates to a diagnostic device and a kit for carrying out the aforementioned method.
摘要翻译：本发明涉及用于医学诊断的方法和装置。具体地说，本发明涉及一种诊断呈现心房颤动的受试者的心力衰竭的方法，该方法包括确定受试者样品中GDF-15的量，并将GDF-15的量与合适的参考量进行比较，从而使心力衰竭被诊断。此外，本发明涉及一种用于执行上述方法的诊断装置和套件。

6. 发明授权

US07955854B2 Assessing heart failure in patients with atrial fibrillation using GDF-15 and natriuretic peptides 有权
标题翻译：使用GDF-15和利尿钠肽评估房颤患者的心力衰竭
公开(公告)号：US07955854B2
公开(公告)日：2011-06-07
申请号：US12621560
申请日：2009-11-19
申请人： Georg Hess , Andrea Horsch , Hendrik Huedig , Dietmar Zdunek
发明人： Georg Hess , Andrea Horsch , Hendrik Huedig , Dietmar Zdunek
IPC分类号： G01N33/68 , G01N33/48
CPC分类号： G01N33/6863 , G01N33/74 , G01N2333/495 , G01N2333/58 , G01N2800/324 , G01N2800/325
摘要： Disclosed are a method, device, and test kit for diagnosing heart failure in a patient exhibiting atrial fibrillation. The method includes determining an amount of growth differentiation factor-15 (GDF -15) in a sample from the patient and comparing the amount of GDF-15 determined with a reference amount of GDF-15, wherein when the amount of GDF-15 determined is greater than the reference amount of GDF-15, a diagnosis of heart failure is indicated.
摘要翻译：公开了用于诊断出呈现心房颤动的患者的心力衰竭的方法，装置和测试试剂盒。该方法包括确定来自患者的样品中的生长分化因子-15（GDF-15）的量，并比较用参考量的GDF-15测定的GDF-15的量，其中当GDF-15的量确定大于参考量的GDF-15，表明心力衰竭的诊断。

7. 发明申请

US20110165591A1 USE OF BIGLYCAN IN THE ASSESSMENT OF HEART FAILURE 审中-公开
标题翻译：大智慧在评估心脏失败时的使用
公开(公告)号：US20110165591A1
公开(公告)日：2011-07-07
申请号：US13048196
申请日：2011-03-15
申请人： Ursula-Henrike Wienhues-Thelen , Sara Arab , Dirk Block , Andrew Emili , Anthony Gramolini , Georg Hess , Hendrik Huedig , Peter Liu , David MacLennan
发明人： Ursula-Henrike Wienhues-Thelen , Sara Arab , Dirk Block , Andrew Emili , Anthony Gramolini , Georg Hess , Hendrik Huedig , Peter Liu , David MacLennan
IPC分类号： G01N33/53
CPC分类号： G01N33/6893 , G01N2333/4722 , G01N2800/325
摘要： The invention relates to a method for assessing heart failure in vitro and involves the steps of measuring in a sample the concentration of the marker biglycan, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for biglycan and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of biglycan as a marker protein in the assessment of heart failure, a marker combination comprising biglycan and a kit for measuring biglycan.
摘要翻译：本发明涉及一种用于评估体外心脏衰竭的方法，包括以下步骤：在样品中测量标记物双糖链球蛋白的浓度，任选地在样品中测量一种或多种其它心力衰竭标志物的浓度，以及通过比较确定的双糖甘肽聚糖浓度和任选的一种或多种其他标记物测定的浓度与该参考群体中确定的该标记物或这些标记物的浓度进行比较来评估心力衰竭。还公开了使用双糖链蛋白作为评估心力衰竭的标记蛋白，包括双糖链蛋白聚糖和用于测量双糖链球蛋白的试剂盒的标记组合。

8. 发明授权

US09267954B2 Use of SLIM-1 in the assessment of heart failure 有权
标题翻译：使用SLIM-1评估心力衰竭
公开(公告)号：US09267954B2
公开(公告)日：2016-02-23
申请号：US12554042
申请日：2009-09-04
申请人： Ursula-Henrike Wienhues-Thelen , Georg Hess , Hendrik Huedig , Herbert von der Eltz , Andrew Emili , Anthony Gramolini , Peter Liu , David MacLennan , Vincent Fong , Ruth Isserlin , Thomas Kislinger , Dirk Block
发明人： Ursula-Henrike Wienhues-Thelen , Georg Hess , Hendrik Huedig , Herbert von der Eltz , Andrew Emili , Anthony Gramolini , Peter Liu , David MacLennan , Vincent Fong , Ruth Isserlin , Thomas Kislinger , Dirk Block
IPC分类号： G01N33/68
CPC分类号： G01N33/6887 , G01N2800/325
摘要： The invention relates to a method for assessing heart failure in vitro comprising the steps of measuring in a sample the concentration of the marker SLIM-1, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for SLIM-1 and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of SLIM-1 as a marker protein in the assessment of heart failure, a marker combination comprising SLIM-1 and a kit for measuring SLIM-1.
摘要翻译：本发明涉及用于评估体外心脏衰竭的方法，包括以下步骤：在样品中测量标记物SLIM-1的浓度，任选地在样品中测量一种或多种其它心力衰竭标志物的浓度，并且通过将针对SLIM-1确定的浓度与为任选的一种或多种其它标记确定的浓度与在参考群体中确定的该标志物或这些标记的浓度进行比较来评估心力衰竭。还公开了在评估心力衰竭中使用SLIM-1作为标记蛋白，包括SLIM-1的标记组合和用于测量SLIM-1的试剂盒。

9. 发明授权

US10234462B2 Use of mimecan in the assessment of heart failure 有权
公开(公告)号：US10234462B2
公开(公告)日：2019-03-19
申请号：US13359276
申请日：2012-01-26
申请人： Dirk Block , Sara Arab , Georg Hess , Hendrik Huedig , Peter Liu , Ursula-Henrike Wienhues-Thelen
发明人： Dirk Block , Sara Arab , Georg Hess , Hendrik Huedig , Peter Liu , Ursula-Henrike Wienhues-Thelen
IPC分类号： G01N33/68
摘要： The disclosure relates to assessing heart failure in vitro by measuring the concentration of the marker mimecan in a sample, and optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration of mimecan and the one or more other marker(s) to reference concentrations of this (or these) marker(s) as established in a reference population. The one or more markers may be selected from the group comprising a natriuretic peptide marker, a cardiac troponin marker, and a marker of inflammation. Also disclosed are the use of mimecan as a marker protein in the assessment of heart failure, a marker combination comprising mimecan, and a kit for measuring mimecan.

10. 发明申请

US20120156703A1 USE OF MIMECAN IN THE ASSESSMENT OF HEART FAILURE 审中-公开
标题翻译： MIMECAN在心脏衰竭评估中的应用
公开(公告)号：US20120156703A1
公开(公告)日：2012-06-21
申请号：US13359276
申请日：2012-01-26
申请人： Dirk Block , Sara Arab , Georg Hess , Hendrik Huedig , Peter Liu , Ursula-Henrike Wienhues-Thelen
发明人： Dirk Block , Sara Arab , Georg Hess , Hendrik Huedig , Peter Liu , Ursula-Henrike Wienhues-Thelen
IPC分类号： G01N33/566
CPC分类号： G01N33/6893 , G01N33/6812 , G01N2333/4703 , G01N2800/325
摘要： The disclosure relates to assessing heart failure in vitro by measuring the concentration of the marker mimecan in a sample, and optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration of mimecan and the one or more other marker(s) to reference concentrations of this (or these) marker(s) as established in a reference population. The one or more markers may be selected from the group comprising a natriuretic peptide marker, a cardiac troponin marker, and a marker of inflammation. Also disclosed are the use of mimecan as a marker protein in the assessment of heart failure, a marker combination comprising mimecan, and a kit for measuring mimecan.
摘要翻译：本公开涉及通过测量样品中标记拟米卡因的浓度来评估体外心力衰竭，并且可选地在样品中测量一种或多种其他心力衰竭标志物的浓度，并通过比较心脏衰竭来评估心力衰竭在参考群体中建立的，将拟米卡宁和一种或多种其它标记物浓度提高至（或这些）标记的参考浓度。一种或多种标志物可以选自利尿钠肽标记物，心肌肌钙蛋白标记物和炎症标志物。还公开了在评估心力衰竭中使用mimecan作为标记蛋白，包括mimecan的标记组合和用于测量mimecan的试剂盒。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式